1. Signaling Pathways
  2. Immunology/Inflammation
  3. Interleukin Related

Interleukin Related

IL

Interleukins are a group of cytokines (secreted proteins and signaling molecules) that were first seen to be expressed by white blood cells (leukocytes). The function of the immune system depends in a large part on interleukins, and rare deficiencies of a number of them have been described, all featuring autoimmune diseases or immune deficiency. The majority of interleukins are synthesized by helper CD4 T lymphocytes, as well as through monocytes, macrophages, and endothelial cells. They promote the development and differentiation of T and B lymphocytes, and hematopoietic cells. Interleukin receptors on astrocytes in the hippocampus are also known to be involved in the development of spatial memories in mice.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-168072
    GP130-IN-1
    GP130-IN-1 (compound 49) is a potent GP130 inhibitor with significant in vitro antitumor activity and higher selectivity than Bazedoxifene (HY-A0031). GP130-IN-1 induces ultrastructural changes in cells, causing cell cycle arrest in the G0/G1 phase in a time-dependent manner and triggering apoptosis and autophagy. GP130-IN-1 can be used in the study of triple-negative breast cancer.
    GP130-IN-1
  • HY-P11600
    SGNLTKYWKKIWKPGIKKWIK
    Inhibitor
    SGNLTKYWKKIWKPGIKKWIK is a thymidylate kinase (TMK)-targeting antimicrobial peptide with a KD value of 4.721 μM. SGNLTKYWKKIWKPGIKKWIK exerts antimicrobial effects through multiple mechanisms, including membrane disruption, induction of ROS, and DNA binding. SGNLTKYWKKIWKPGIKKWIK shows remarkable activity against Gram-negative bacteria, possesses good biocompatibility, and rarely induces drug resistance. SGNLTKYWKKIWKPGIKKWIK can be used for research on Gram-negative bacterial infections.
    SGNLTKYWKKIWKPGIKKWIK
  • HY-155821
    Anti-inflammatory agent 55
    Inhibitor
    Anti-inflammatory agent 55 (compound 9j) is a derivative of Coixol and has anti-inflammatory activity. Anti-inflammatory agent 54 inhibits the NF-κB pathway and downregulates the expression of iNOS, TNF-α, IL-6 and IL-1β. Anti-inflammatory agent 54 inhibits LPS-induced nitric oxide (NO) production in RAW264.7 macrophages (IC50: 0.8 μM) and exerts in vivo anti-inflammatory activity in a mouse auricular edema model.
    Anti-inflammatory agent 55
  • HY-175771
    STAT3-IN-46
    Inhibitor
    STAT3-IN-46 is a selective and orally active inhibitor of signal transducer and activator of transcription 3 (STAT3) (KD = 323.3 nM). STAT3-IN-46 directly binds to the SH2 domain of the STAT3 and inhibits IL-6/JAK/STAT3 signaling pathway (IC50 = 0.87 μM) and downregulates c-Myc and Bcl-2 levels. STAT3-IN-46 can be used for the research of cancer, such as triple-negative breast cancer.
    STAT3-IN-46
  • HY-P990451
    Anti-IL-3Ra/CD123 Antibody (SNG-CD123A)
    Inhibitor
    Anti-IL-3Ra/CD123 Antibody (SNG-CD123A) is a CHO-expressed human antibody that targets IL-3Ra/CD123. The predicted molecular weight (MW) of Anti-IL-3Ra/CD123 Antibody (SNG-CD123A) is 146.14 kDa. The isotype control for Anti-IL-3Ra/CD123 Antibody (SNG-CD123A) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-IL-3Ra/CD123 Antibody (SNG-CD123A)
  • HY-P10935
    Amilo-5MER
    Inhibitor
    Amilo-5MER (5-MP) is an orally active and selective Serum Amyloid A (SAA) inhibitor. Amilo-5MER specifically inhibits the release of pro-inflammatory cytokines IL-6 and IL-1β from SAA-activated cells. Amilo-5MER reduces chronic inflammation and relieves symptoms of diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and multiple sclerosis (MS). Amilo-5MER is promising for research of autoimmune diseases and chronic inflammatory diseases.
    Amilo-5MER
  • HY-114573
    TNF-α-IN-19
    Inhibitor
    TNF-α-IN-19 is an inhibitor of TNFα that can block the interaction between TNFαRI, TRADD, and RIP1, the EC50 values for TNFα, IL-1β, and IL-1β/TNFα are 2.451, 3.792 and 1.54 μM, respectively. TNF-α-IN-19 only inhibits the degradation of IκBα when cells are stimulated by TNFα and not by IL-1β.
    TNF-α-IN-19
  • HY-176274
    FASN/SCD-IN-1
    Inhibitor
    FASN/SCD-IN-1 is a Silybin (HY-N0779A) derivative, an orally active inhibitor of Fatty Acid Synthase (FASN)/Stearoyl-CoA Desaturase (SCD). FASN/SCD-IN-1 has shown in vitro activity in inhibiting lipid deposition, reducing FASN and SCD transcriptional levels, and exhibiting antioxidant, anti-inflammatory, and anti-fibrotic activities. FASN/SCD-IN-1 has demonstrated significant hepatoprotective effects in a rat model of acute liver injury. FASN/SCD-IN-1 ameliorates the pathological features of MASH liver, including steatosis, inflammation, and fibrosis in a mouse model of myeloproliferative steatohepatitis (MASH). FASN/SCD-IN-1 can be used to study MASH.
    FASN/SCD-IN-1
  • HY-167845
    LD03-DEX
    Inhibitor
    LD03-DEX is a precursor compound of dexamethasone (HY-14648) with immunosuppressive activity.
    LD03-DEX
  • HY-14575
    Nastorazepide hemicalcium
    Inhibitor
    Nastorazepide (Z-360) hemicalcium is an orally active 1,5-benzodiazepine derivative and gastrin/CCK-2 receptor antagonist. Nastorazepide hemicalcium inhibits the specific binding of [3H]CCK-8 to the human CCK-2 receptor with a Ki value of 0.47 nM. Nastorazepide hemicalcium inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and NR2B phosphorylation. Nastorazepide hemicalcium has antitumor activity against pancreatic cancer. Nastorazepide hemicalcium inhibits colorectal cancer liver metastasis and relieves pain.
    Nastorazepide hemicalcium
  • HY-180155
    Keap1/Nrf2/ARE activator 2
    Inhibitor
    Keap1/Nrf2/ARE activator 2 is an activator of Keap1/Nrf2/ARE pathway and non-competitively inhibits AChE with an IC50 of 14.79 μM and a Ki of 1.35 μM. Keap1/Nrf2/ARE activator 2 promotes Nrf2 nuclear translocation, leading to antioxidant gene upregulation and enhanced cellular defense against oxidative stress. Keap1/Nrf2/ARE activator exhibits robust neuroprotection against both H2O2- and Scopolamine (SCA) (HY-N0296)-induced injury in PC12 cells. Keap1/Nrf2/ARE activator 2 ameliorates memory impairment and the neuro-inflammation associated with SCA-initiated cognitive dysfunction in a zebrafish model. Keap1/Nrf2/ARE activator 2 can be used for the research of Alzheimer's disease.
    Keap1/Nrf2/ARE activator 2
  • HY-183607
    SMU-3k
    Activator
    SMU-3k is a STING activator and PD-L1 inhibitor, with a PD-L1 IC50 of 106 nM, a KD of 386 nM for human PD-L1, and a KD of 352 nM for murine PD-L1. SMU-3k activates the STING pathway, induces phosphorylation of TBK1 and IRF3, and promotes the expression of IFN-β, IL-6 and CXCL10. SMU-3k blocks the PD-1/PD-L1 interaction, reduces PD-L1 levels and induces PD-L1 internalization. Through dual immunomodulation, SMU-3k exerts synergistic tumor growth inhibitory effects in a mouse colon cancer model. SMU-3k can be used for the research of colon cancer.
    SMU-3k
  • HY-N17853
    Siaresinolic acid
    Siaresinolic acid is a compound found in the leaves of Sabicea grisea. Siaresinolic acid shows antinociceptive and anti-inflammatory activity. Siaresinolic acid reduces nociceptive behavior by ATP-dependent potassium channel, inhibits leukocyte influx, plasma leakage, and proinflammatory mediator (TNF-α, IL-1β) production. Siaresinolic acid does not induce cytotoxicity in murine macrophages, alter locomotor activity at high doses. Siaresinolic acid can be used for the research of pleurisy and pain.
    Siaresinolic acid
  • HY-153330
    TNF-α-IN-10
    Inhibitor
    TNF-α-IN-10 (compound 8a) is a IL-6 and TNF-α inhibitor. TNF-α-IN-10 shows anti-inflammatory activity.
    TNF-α-IN-10
  • HY-181827
    IL-17-IN-7
    Inhibitor
    IL-17-IN-7 (Compound 23) is a IL-17 inhibitor with a pIC50 of 7.1 against IL-17A.
    IL-17-IN-7
  • HY-126042R
    (±)-Lisofylline (Standard)
    Inhibitor
    (±)-Lisofylline (Standard) is the analytical standard of (±)-Lisofylline. This product is intended for research and analytical applications. (±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research.
    (±)-Lisofylline (Standard)
  • HY-181818
    4,5-Dehydro-6-oxoallosecurinine
    Inhibitor
    4,5-Dehydro-6-oxoallosecurinine is a Keap1-Nrf2 pathway activator. 4,5-Dehydro-6-oxoallosecurinine promotes the nuclear translocation of Keap1-Nrf2, and induces the expression of antioxidant and cytoprotective genes. 4,5-Dehydro-6-oxoallosecurinine reduces the production of NO, and decreases the levels of iNOS, TNF-α, IL-6 and IL-1β in LPS-stimulated microglia. 4,5-Dehydro-6-oxoallosecurinine can be used for the research of neurodegenerative diseases.
    4,5-Dehydro-6-oxoallosecurinine
  • HY-B0513R
    Methylthiouracil (Standard)
    Inhibitor
    Methylthiouracil (Standard) is the analytical standard of Methylthiouracil. This product is intended for research and analytical applications. Methylthiouracil is an antithyroid agent. Methylthiouracil suppresses the production TNF-α and IL-6, and the activation of NF-κB and ERK1/2.
    Methylthiouracil (Standard)
  • HY-P992248
    Anti-IL-32 Antibody
    Anti-IL-32 Antibody is a monoclonal antibody that targets IL-32. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-IL-32 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-IL-32 Antibody
  • HY-107352R
    Fosfenopril (Standard)
    Inhibitor
    Fosfenopril (Standard) is the analytical standard of Fosfenopril. This product is intended for research and analytical applications. Fosfenopril (Fosinoprilat) is a potent angiotensin converting enzyme (ACE) inhibitor. Fosfenopril alleviates lipopolysaccharide (LPS)-induced inflammation by inhibiting TLR4/NF-κB signaling in monocytes.
    Fosfenopril (Standard)
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.